There are currently 2033 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC Norris Comprehensive Cancer Center, Children's Hospital Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Harmony TPV Post-Approval Study
NCT05077774
Recruiting
The purpose of this study is to characterize the functionality of transcatheter implantation of the Medtronic Harmony Transcatheter Pulmonary Valve (TPV) achieved by real-world implanters.
Gender:
All
Ages:
All
Trial Updated:
04/04/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation
Register for Updates
A Study to Assess EN3835 in the Treatment of Plantar Fasciitis (PFA)
NCT06169319
Recruiting
This study will assess the efficacy, safety, and tolerability of 2 different doses of EN3835 compared to placebo.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/04/2024
Locations: Endo Site 16, Los Angeles, California
Conditions: Plantar Fasciitis
Register for Updates
Study of PYX-106 in Solid Tumors
NCT05718557
Recruiting
The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Solid Tumor
Register for Updates
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
NCT03645928
Recruiting
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/04/2024
Locations: University of Southern California, Los Angeles, California +1 locations
Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Register for Updates
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: University of Southern California, Los Angeles, California +1 locations
Conditions: Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC)
Register for Updates
PV Loop & Coarctation Study
NCT05362721
Recruiting
Coarctation of the aorta accounts for 4-7% of all congenital heart disease. While stent therapy, when feasible, is the standard of care for coarctation, it may not completely improve the work (and afterload) of the heart due to its effects on the elasticity of the aorta. This study will provide the information needed to understand the effects of current management on the cardiac mechanics and work.
Gender:
All
Ages:
6 years and above
Trial Updated:
04/04/2024
Locations: Children's Hospital of Los Angeles, Los Angeles, California
Conditions: Coarctation of Aorta
Register for Updates
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
NCT04201457
Recruiting
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type... Read More
Gender:
All
Ages:
Between 1 year and 30 years
Trial Updated:
04/03/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
Register for Updates
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: University of California-Los Angeles, Los Angeles, California
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Register for Updates
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
NCT04090424
Recruiting
This is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/03/2024
Locations: Southern California Regional Burn Center at LAC+USC, Los Angeles, California
Conditions: Burns
Register for Updates
Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans
NCT05120635
Recruiting
Anxiety disorders such as post-traumatic stress disorder (PTSD) and generalized anxiety disorder (GAD) affect a large number of individuals with a significant portion of patients failing to improve with current treatments. The purpose of this study is to understand the brain mechanisms that produce fear and anxiety in humans. To accomplish this goal, we will measure the brain activity along with the heart rate and skin perspiration of patients while they are completing tasks on a computer. Some... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/03/2024
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Fear, GAD, Emotional Memory, PTSD
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Kaiser Permanente Los Angeles Medical Center, Los Angeles, California +3 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Transanastomotic Tube for Proximal Esophageal Atresia With Distal Tracheoesophageal Fistula Repair
NCT03730454
Recruiting
This trial will compare the effectiveness of two common surgical practices for Type C esophageal atresia repair: esophageal atresia (EA) with distal tracheoesophageal fistula (TEF). Infants with EA/TEF requiring surgical intervention will be recruited. Subjects will be randomized to either repair with or without transanstomotic tube (TT) during esophageal anastomosis creation. Primary outcome is symptomatic anastomotic stricture development requiring dilation within 12 months.
Gender:
All
Ages:
6 months and below
Trial Updated:
04/03/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Esophageal Atresia, Tracheoesophageal Fistula
Register for Updates